AnaptysBio ANAB
$ 14.43
-3.8%
Quarterly report 2024-Q3
added 11-05-2024
AnaptysBio Balance Sheet 2011-2024 | ANAB
Annual Balance Sheet AnaptysBio
2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-18.2 M | -51.9 M | -475 M | - | -170 M | -105 M | -66.8 M | -37.4 M | -46.8 M | -17.4 M | -1.99 M | - | - |
Long Term Debt |
16 M | 17.8 M | 19.4 M | - | - | 625 K | 7.55 M | 13.8 M | 4.9 M | 4.79 M | - | - | - |
Long Term Debt Current |
1.78 M | 1.64 M | 1.5 M | 342 K | 871 K | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 654 K | 796 K | 7.69 M | 17.2 M | 6.57 M | 7.39 M | 607 K | - | - |
Total Current Liabilities |
37.4 M | 26.1 M | 16.1 M | 19.8 M | 29.5 M | 21.8 M | 14.1 M | - | - | - | - | - | - |
Total Liabilities |
- | - | - | - | 30.2 M | 22.6 M | 21.8 M | 22.9 M | 13.9 M | 19.1 M | 3.77 M | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | 2.94 M | 10.1 M | 1.29 M | - | - |
Retained Earnings |
-614 M | -450 M | -322 M | -264 M | -244 M | -147 M | -85 M | -54.9 M | -50.7 M | -45.3 M | -48.8 M | - | - |
Total Assets |
452 M | 610 M | 643 M | 417 M | 435 M | 509 M | 329 M | 62.2 M | 56.3 M | 25.1 M | 3.91 M | - | - |
Cash and Cash Equivalents |
36 M | 71.3 M | 496 M | 251 M | 171 M | 114 M | 81.2 M | 51.3 M | 51.7 M | - | - | - | - |
Book Value |
452 M | 610 M | 643 M | 417 M | 405 M | 486 M | 308 M | 39.3 M | 42.3 M | 5.99 M | 145 K | - | - |
Total Shareholders Equity |
88.1 M | 262 M | 356 M | 397 M | 405 M | 486 M | 308 M | -38.2 M | -35.2 M | - | - | - | - |
All numbers in USD currency
Quarterly Balance Sheet AnaptysBio
2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
14.6 M | 15.1 M | 15.6 M | 16 M | 16.5 M | 16.9 M | 17.4 M | 17.8 M | 18.2 M | 18.7 M | 19.1 M | 19.4 M | 19.8 M | 20.2 M | - | - | - | - | 419 K | 654 K | 654 K | 654 K | 654 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Retained Earnings |
-738 M | -705 M | -658 M | -614 M | -572 M | -535 M | -495 M | -450 M | -424 M | -391 M | -358 M | -322 M | -289 M | -283 M | -282 M | -264 M | -264 M | -264 M | -264 M | -244 M | -244 M | -244 M | -244 M | -147 M | -147 M | -147 M | -147 M | -85 M | -85 M | -85 M | -85 M | -54.9 M | -54.9 M | -54.9 M | -54.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
493 M | 427 M | 406 M | 452 M | 487 M | 517 M | 552 M | 610 M | 619 M | 604 M | 625 M | 643 M | 424 M | 427 M | 396 M | 417 M | 417 M | 417 M | 417 M | 435 M | 435 M | 435 M | 435 M | 509 M | 509 M | 509 M | 509 M | 329 M | 329 M | 329 M | 329 M | 62.2 M | 62.2 M | 62.2 M | 62.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
192 M | 71.8 M | 53.7 M | 36 M | 26.3 M | 35.2 M | 94.6 M | 71.3 M | 58.5 M | 71.7 M | 166 M | 496 M | 336 M | 332 M | 284 M | 251 M | 250 M | 250 M | 250 M | 171 M | 171 M | 171 M | 171 M | 114 M | 114 M | 114 M | 114 M | 81.2 M | 81.2 M | 81.2 M | 81.2 M | 51.2 M | 51.2 M | 51.2 M | 51.2 M | 51.7 M | - | - | - | 22.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
493 M | 427 M | 406 M | 452 M | 487 M | 517 M | 552 M | 610 M | 619 M | 604 M | 625 M | 643 M | 424 M | 427 M | 396 M | 417 M | 417 M | 417 M | 417 M | 435 M | 435 M | 435 M | 435 M | 509 M | 509 M | 509 M | 509 M | 329 M | 329 M | 329 M | 329 M | 62.2 M | 62.2 M | 62.2 M | 62.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
84.4 M | 9.88 M | 47.8 M | 88.1 M | 120 M | 148 M | 191 M | 262 M | 278 M | 304 M | 331 M | 356 M | 384 M | 386 M | 382 M | 397 M | 397 M | 397 M | 397 M | 405 M | 405 M | 405 M | 405 M | 486 M | 486 M | 486 M | 486 M | 308 M | 308 M | 308 M | 308 M | -38.2 M | -38.2 M | -38.2 M | -38.2 M | -35.2 M | - | - | - | -30.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency